We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Potential Vaccine Prevents Chronic Urinary Tract Infections

By LabMedica International staff writers
Posted on 04 Oct 2016
A team of molecular microbiologists has developed a potential vaccine to prevent acute Escherichia coli urinary tract infections (UTIs) from becoming chronic.

About 80% of UTIs are caused by uropathogenic E. More...
coli (UPEC). Acute UTIs are characterized by frequent painful urination and abdominal or back pain and typically are treated with antibiotics. Chronic infections allow a pool of bacteria to survive in the bladder and possibly spread to the kidneys or the bloodstream, where they can cause severe disease.


UPEC express CUP pili, which are extracellular fibers tipped with adhesion proteins that bind mucosal surfaces of the urinary tract. Type 1 pili are necessary in the early stages of infection, while a second pilus, called Fml, is encoded by genes similar to those responsible for the type 1 pilus but whose function has not been known.

Investigators at Washington University School of Medicine (St. Louis, MO, USA) genetically engineered a strain of E.coli to lack the gene for the FmlH protein, which is located at the tip of Fml pili and enable the pili to attach to the bladder.

The investigators reported in the September 22, 2016, online edition of the journal Cell Host & Microbe that deletion of FmlH had no effect on UPEC virulence in an acute mouse model of cystitis. However, FmlH provided a fitness advantage during chronic cystitis, which was manifested as persistent bacteriuria, high bladder bacterial burdens, and chronic inflammation. In situ binding confirmed that FmlH bound avidly to the inflamed, but not the naive bladder.

Overall, E. coli lacking FmlH were less likely to establish chronic infections in mice than bacteria with the intact protein. In the initial phase of acute infection, the two strains multiplied to similar levels. However, by the end of the fourth week, the bacteria without FmlH were 1,000 times less numerous in the bladder and 100 times less numerous in the kidneys than the bacteria with the protein.

Vaccination with purified FmlH protein significantly protected mice from developing chronic cystitis following infection with the wild type E. coli.

“Our findings reveal how bacteria have evolved a mechanism to colonize the bladder in order to persist and cause UTIs, and our vaccination study suggests that inhibiting this mechanism could be part of a viable approach to treating or preventing these infections,” said senior author Dr. Scott Hultgren, professor of molecular microbiology at Washington University School of Medicine.

Related Links:
Washington University School of Medicine



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Integrated Biochemical & Immunological System
Biolumi CX8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.